Mucormycosis: A deadly black fungus infection among COVID-19 patients in India

After first phase of Covid-19, the second wave affects a lot to the Indians with mysterious fungal infection known as Mucormycosis. Here, we reviewed clinical pathogenesis, signs, symptoms and treatment against black fungus. The conclusion revealed that use of immunosuppressant to combat Covid-19 also increases the risk to get infected with mucormycosis. Patients with hyperglycemia, ketoacidosis, solid organ or bone marrow transplantion, liver cirrhosis, neutropenia are more susceptible to get attacked by Mucormycosis moulds. Early diagnosis, removal of predisposing factors, timely antifungal therapy with surgical removal of all infected tissues and adjunctive therapies are four major factors to eradicate Mucormycosis.

Automated summary

After the first phase of Covid-19, Indians are facing a new challenge of mucormycosis, also known as black fungus. The use of immunosuppressants to treat Covid-19 has been identified as a risk factor for getting infected with mucormycosis. Early diagnosis, removal of predisposing factors, timely antifungal therapy with surgical removal of infected tissues are crucial in eradicating mucormycosis.